Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas R Fleming

Showing results (41-50 of 109) with videos related to

Pageof 11
Sort By:
JAMA|March 23, 2026
Reflections on FDA Draft Guidance on Bayesian Methods in Trials-Protecting Scientific Integrity and Evidentiary StandardsScott R Evans, Thomas R Fleming, Holly Janes, et al.
Drug Information Journal|June 23, 2012
Testing in a Prespecified Subgroup and the Intent-to-Treat PopulationMark D Rothmann, Jenny J Zhang, Laura Lu, et al.
Journal of Biopharmaceutical Statistics|June 14, 2014
Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trialsThomas R Fleming, Charles H Hennekens, Marc A Pfeffer, et al.
Biometrics|March 23, 2011
Insights on the robust variance estimator under recurrent-events modelHussein R Al-Khalidi, Yili Hong, Thomas R Fleming, et al.
Clinical Trials (London, England)|August 13, 2011
Some essential considerations in the design and conduct of non-inferiority trialsThomas R Fleming, Katherine Odem-Davis, Mark D Rothmann, et al.
The Journal of Infectious Diseases|April 21, 2022
Reliably Assessing Duration of Protection for Coronavirus Disease 2019 VaccinesDan-Yu Lin, Donglin Zeng, Yu Gu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 15, 2013
Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventionsDeborah Donnell, James P Hughes, Lei Wang, et al.
Lancet (London, England)|August 31, 2020
COVID-19 vaccine trials should seek worthwhile efficacyPhilip Krause, Thomas R Fleming, Ira Longini, et al.
Lancet (London, England)|October 30, 2020
Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essentialPhilip R Krause, Thomas R Fleming, Susan S Ellenberg, et al.
Clinical Trials (London, England)|April 1, 2008
Maintaining confidentiality of interim data to enhance trial integrity and credibilityThomas R Fleming, Katrina Sharples, John McCall, et al.
Pageof 11

Showing results (41-50 of 109) with videos related to

Sort By:
Pageof 11
JAMA|March 23, 2026
Reflections on FDA Draft Guidance on Bayesian Methods in Trials-Protecting Scientific Integrity and Evidentiary StandardsScott R Evans, Thomas R Fleming, Holly Janes, et al.
Drug Information Journal|June 23, 2012
Testing in a Prespecified Subgroup and the Intent-to-Treat PopulationMark D Rothmann, Jenny J Zhang, Laura Lu, et al.
Journal of Biopharmaceutical Statistics|June 14, 2014
Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trialsThomas R Fleming, Charles H Hennekens, Marc A Pfeffer, et al.
Biometrics|March 23, 2011
Insights on the robust variance estimator under recurrent-events modelHussein R Al-Khalidi, Yili Hong, Thomas R Fleming, et al.
Clinical Trials (London, England)|August 13, 2011
Some essential considerations in the design and conduct of non-inferiority trialsThomas R Fleming, Katherine Odem-Davis, Mark D Rothmann, et al.
The Journal of Infectious Diseases|April 21, 2022
Reliably Assessing Duration of Protection for Coronavirus Disease 2019 VaccinesDan-Yu Lin, Donglin Zeng, Yu Gu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 15, 2013
Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventionsDeborah Donnell, James P Hughes, Lei Wang, et al.
Lancet (London, England)|August 31, 2020
COVID-19 vaccine trials should seek worthwhile efficacyPhilip Krause, Thomas R Fleming, Ira Longini, et al.
Lancet (London, England)|October 30, 2020
Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essentialPhilip R Krause, Thomas R Fleming, Susan S Ellenberg, et al.
Clinical Trials (London, England)|April 1, 2008
Maintaining confidentiality of interim data to enhance trial integrity and credibilityThomas R Fleming, Katrina Sharples, John McCall, et al.
Pageof 11